Metabolic Score for Insulin Resistance (METS-IR)

Q: What is the clinical evidence from this study?

Study design: Review. Population: Insulin resistance and cardiometabolic risk. Intervention: Metabolic Score for Insulin Resistance (METS-IR) vs. Euglycemic-hyperinsulinemic clamp (EHC), insulin-based indices (HOMA-IR, QUICKI), and lower METS-IR percentile groups. Primary outcome: Correlation with clamp-measured insulin sensitivity and prediction of incident type 2 diabetes and cardiometabolic outcomes (HR 3.91).

Q: What does this research mean for the field?

The Metabolic Score for Insulin Resistance (METS-IR) correlates inversely with clamp-measured insulin sensitivity and predicts incident type 2 diabetes and cardiometabolic outcomes, serving as a practical non-insulin-based surrogate marker. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Michelle Diane Lundholm

doi:10.65357/001c.172656

October 26, 2026Evidence to Action Official Journal of MDCalc

Metabolic Score for Insulin Resistance (METS-IR)

View Full Paper

Ask AI

Bookmark

Share

Key result

Elevated METS-IR is linked to ~3.9-fold higher risk of incident type 2 diabetes.

HR 3.91

Why the study?

The Metabolic Score for Insulin Resistance (METS-IR) is associated with various cardiometabolic outcomes, but most studies rely on population-based percentile comparisons rather than a single validated threshold, hindering clinical interpretation of individual patient values.

Does the Metabolic Score for Insulin Resistance (METS-IR) accurately approximate insulin resistance and predict cardiometabolic outcomes in adults?

Structured PICO

Does the Metabolic Score for Insulin Resistance (METS-IR) accurately approximate insulin resistance and predict cardiometabolic outcomes in adults?

P

Population

Multiple observational cohorts predominantly across Latin American, Asian, and United States populations evaluated for insulin resistance and incident cardiometabolic outcomes using routine fasting metabolic parameters.

E

Exposure

Metabolic Score for Insulin Resistance (METS-IR), a non-insulin-based surrogate index derived from fasting glucose, triglycerides, BMI, and HDL-C using the formula: (ln((2 × fasting glucose) + triglycerides) × BMI) / (ln(HDL-C)).

C

Comparator

Euglycemic-hyperinsulinemic clamp (EHC) and other surrogate indices of insulin resistance (HOMA-IR, QUICKI, TyG, TG/HDL-C, Matsuda, and Belfiore indices).

O

Outcome

Correlation with clamp-measured insulin sensitivity and association with incident cardiometabolic outcomes (type 2 diabetes, hypertension, kidney disease, stroke, ischemic heart disease, heart failure outcomes, coronary artery calcification, major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality).composite

Main Result

Hazard Ratio: 3.91

METS-IR is a practical, inexpensive, non-insulin-based adjunctive marker that correlates with insulin resistance and predicts cardiometabolic outcomes in epidemiologic research, though the lack of standardized clinical thresholds limits its utility for individual patient decision-making.

Limitations

Most data on METS-IR are observational, often retrospective, and rely on a single baseline measurement rather than dynamic trajectories.
Validation cohorts are predominantly in Latin American, Asian, and U.S. populations, limiting generalizability to other racial and ethnic groups.
No universally accepted or validated clinical cutoff exists, with most studies relying on population-based tertiles or quartiles.
Nonlinear or U-shaped associations are observed for some outcomes such as hypertension and mortality, complicating interpretation.
Component variables can be altered by antihyperglycemic, lipid-lowering, or anti-obesity therapies independent of true changes in insulin sensitivity.
Components are susceptible to transient variation from acute illness, hospitalization, stress, dietary fluctuation, alcohol use, or improper fasting.
Does not capture relevant risk factors such as smoking, physical activity, family history, visceral adiposity, or muscle mass.
Most studies rely on population-based percentile comparisons (tertiles or quartiles) rather than a single validated threshold, hindering individual-level clinical interpretation.
The majority of data on METS-IR are observational, often retrospective, and rely on a single baseline measurement rather than dynamic trajectories.
Validation cohorts are predominantly in Latin American, Asian, and U.S. populations, making generalizability to other racial and ethnic groups less clear.
Nonlinear or U-shaped associations are observed for some outcomes (e.g., hypertension, mortality), complicating simple cutoff-based interpretation.
Component variables can be altered by pharmacotherapy (antihyperglycemic, lipid-lowering, anti-obesity agents) or transient acute conditions (illness, stress, improper fasting) independent of true changes in insulin sensitivity.

Implication

Supports METS-IR as a practical surrogate for insulin sensitivity; confirms associations but leaves open validated thresholds for clinical use.

Abstract

The Metabolic Score for Insulin Resistance (METS-IR) is a non–insulin-based surrogate marker of insulin resistance derived from routine metabolic parameters (fasting glucose, triglycerides, BMI, and HDL-C) that has been studied across largely Latin American, Asian, and United States cohorts. Originally shown to correlate with clamp-measured insulin sensitivity, METS-IR has been associated with cardiometabolic outcomes including incident type 2 diabetes, hypertension, kidney disease, stroke, ischemic heart disease, heart failure outcomes, coronary artery calcification, major adverse cardiovascular events, and both cardiovascular-related and all-cause mortality. Collectively, the literature supports METS-IR as a practical and inexpensive adjunctive marker for approximating insulin resistance. However, a significant methodological limitation is that most studies rely on population-based percentile comparisons rather than a single validated threshold, which substantially hinders the interpretation of individual patient values in clinical practice.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Michelle Diane Lundholm (2026) conducted a review in Insulin resistance and cardiometabolic risk. Metabolic Score for Insulin Resistance (METS-IR) vs. Euglycemic-hyperinsulinemic clamp (EHC), insulin-based indices (HOMA-IR, QUICKI), and lower METS-IR percentile groups was evaluated on Correlation with clamp-measured insulin sensitivity and prediction of incident type 2 diabetes and cardiometabolic outcomes (HR 3.91). METS-IR correlates inversely with clamp-measured insulin sensitivity (r=-0.62, AUC 0.84) and predicts incident type 2 diabetes (highest quartile >50.39 adjusted HR 3.91).

synapsesocial.com/papers/6ae13d36043bfbd635332a16 https://doi.org/10.65357/001c.172656

View Full Paper

Ask AI

Bookmark

Share

Metabolic Score for Insulin Resistance (METS-IR)

Structured PICO

Main Result

Limitations

Implication

Abstract

Discussion

Cite This Study

Metabolic Score for Insulin Resistance (METS-IR)

Structured PICO

Main Result

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading